Regulatory News Service (RNS)

View all

Results, Reports and Presentations

• Indivior FY and Q4 2024 Financial Results

  February 20 2025 Download (589KB)

• Indivior Announces Q3 2024 Financial Results

  October 24 2024 Download (334KB)

• Q2 2024 Results In Line with Updated Guidance; $100m Share Buyback Announced

  July 25 2024 Download (637KB)

• 2024 Jefferies Global Healthcare Conference

  June 5 2024 Download (905KB)

• Analyst Teach-in

  May 23 2024 Download (4.82MB)

View all

Latest News

• Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

  February 27 2025

• Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

  February 24 2025

• Indivior Announces FY and Q4 2024 Financial Results

  February 20 2025

• Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

  February 12 2025

• Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

  November 19 2024

View all